ReviewCells2026
Clockophagy in Alzheimer's Disease: An Emerging Hypothesis Linking Circadian Dysfunction to Ferroptotic Vulnerability.
Review in Cells, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Alzheimer's disease (AD) is frequently associated with sleep disturbances and circadian dysfunction, which may precede or accompany clinical manifestations and have been associated with amyloid-β (Aβ) pathology, tau abnormalities, oxidative stress, lipid peroxidation, and neuronal vulnerability. Increasing evidence suggests that circadian regulation intersects with multiple cellular processes implicated in AD pathogenesis, including autophagy and ferroptosis. Among these mechanisms, clockophagy, an SQSTM1/p62-mediated selective autophagic process involved in BMAL1 degradation, has recently emerged as a potential molecular link between circadian regulation and cellular stress responses. In this review, we summarize current evidence connecting sleep disruption, circadian dysfunction, lipid peroxidation, and ferroptotic susceptibility in AD, while highlighting the current limitations of mechanistic evidence. We further discuss the molecular basis of clockophagy and its potential relationship with BMAL1 regulation, oxidative lipid damage, and ferroptosis. Collectively, clockophagy is currently viewed as an emerging hypothesis that may contribute to AD-related pathological processes. Finally, we discuss potential therapeutic implications, including approaches targeting sleep and circadian organization, BMAL1-associated regulatory pathways, and lipid oxidative stress. Further studies are required to determine whether modulation of clockophagy can influence AD-related neurodegenerative processes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.